Short answer: most people on semaglutide get nausea, and most of it is over within days. In pooled data from the STEP obesity trials, 43.9% of participants on semaglutide 2.4 mg reported nausea versus 16.1% on placebo — but 98.1% of gastrointestinal events were mild or moderate, 99.5% were non-serious, and the median episode of nausea lasted 8 days.1 Constipation is the exception: it lasts much longer, a median of 47 days.
The events do not run continuously for months. They cluster around each dose increase and settle down between them, which is why the label raises the dose in four-week steps. The serious risks are real but uncommon: gallbladder disease is the best-documented one, and pancreatitis, bowel obstruction, kidney injury from dehydration and a rodent-based thyroid-tumour warning make up the rest. Across the largest pooled analysis to date — 99,599 patients on GLP-1 drugs — gastrointestinal disorders rose 63% and gallbladder disorders 26%, with no significant increase in pancreatitis, stroke or new cancers.2
This is a research reference summarising published trial and regulatory data, not medical advice. Every frequency below comes from regulated pharmaceutical semaglutide (Ozempic, Wegovy); the final section explains why none of it transfers to unverified research-grade material.
What most people actually feel, and how often
The table below runs from most frequent to most serious. Percentages are from the 2.4 mg weight-management dose unless noted. Every row is human clinical data — trial, regulatory label or pharmacovigilance — except thyroid C-cell tumours, which are rodent findings only.
| Effect | How common | Evidence |
|---|---|---|
| Nausea | 43.9% vs 16.1% placebo; usually mild-moderate, worst around dose increases | Pooled STEP 1–3 (Wharton 2022)1 |
| Diarrhoea | 29.7% vs 15.9% placebo | Pooled STEP 1–31 |
| Vomiting | 24.5% vs 6.3% placebo | Pooled STEP 1–31 |
| Constipation | 24.2% vs 11.1% placebo; the longest-lasting of the four | Pooled STEP 1–31 |
| Abdominal pain | Common (~20%) | FDA Wegovy label3 |
| Mild hair thinning | ~3%; on the label, not anecdotal | FDA Wegovy label3 |
| Gallbladder disease / gallstones | Clearly increased: +26% in the 99,599-patient pooled analysis, and roughly 2.6× placebo in obesity trials | Galli 20252; Safwan 20254 |
| Acute pancreatitis | Rare. A labelled warning and a real-world reporting signal, but not a significant increase in randomised-trial meta-analyses | FDA label3; Sodhi 20235; Galli 20252 |
| Bowel obstruction / gastroparesis | Rare but serious; reported disproportionately versus other weight-loss agents | Sodhi 20235 |
| Acute kidney injury | Rare; happens through dehydration from heavy vomiting or diarrhoea | FDA label3 |
| Worsening diabetic retinopathy | 3.0% vs 1.8% placebo in type-2 diabetes; linked to fast glucose lowering, not the drug itself | SUSTAIN-6 programme3 |
| Aspiration under anaesthesia | A recognised concern because the stomach empties more slowly; matters before surgery or sedation | FDA label3 |
| Thyroid C-cell tumours | Rodent data only. Human relevance undetermined; carries a boxed warning | FDA boxed warning3 |
When side effects start, and how long they last
This is the question the frequency tables never answer, and it has a documented answer. The pooled STEP analysis followed 2,117 people on semaglutide and 1,262 on placebo for 68 weeks and measured how long each episode lasted.1
| Symptom | Median duration of an episode (semaglutide 2.4 mg) |
|---|---|
| Nausea | 8 days |
| Diarrhoea | 3 days |
| Vomiting | 2 days |
| Constipation | 47 days (35 days on placebo); prevalence levelled off around week 10 |
Two things follow from this. First, the nausea people describe as “lasting months” is usually a series of short episodes triggered by successive dose increases, not one continuous symptom. Second, constipation behaves differently from the rest — it is slower to appear, lasts far longer, and is the one that tends to persist into maintenance dosing.
Over the whole 68 weeks, 4.3% of people on semaglutide stopped treatment permanently because of gastrointestinal events.1 In the STEP 1 trial specifically, that figure was 4.5% versus 0.8% on placebo.6 Put the other way round: about 95 people in 100 tolerated it well enough to continue.
Why the nausea returns every time the dose goes up
The approved weight-management schedule increases the dose in five steps, four weeks apart: 0.25 mg weekly for weeks 1–4, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching the 2.4 mg maintenance dose at week 17.3 The trial data show gastrointestinal events occurring “most frequently during or shortly after dose escalation”.1 Those two facts explain the pattern people report: a rough week after each step up, then a calmer stretch, then another rough week.
The whole point of that slow schedule is tolerability — it exists because starting at the full dose is far harder to tolerate. Whether a given person moves up faster, slower, or pauses at a step is a clinical decision for their prescriber, and one of the practical reasons unsupervised use is a poor idea.
One finding worth knowing, because it removes a common worry: weight loss did not depend on feeling sick. Average weight loss was similar in participants who had no gastrointestinal events (9.6–17.1%) and those who did (11.4–17.7%), and a mediation analysis attributed less than one percentage point of the extra weight loss to those events.1 Nausea is not the mechanism.
The serious risks, in proportion
Two claims get made about semaglutide, and both are wrong. One is that it is essentially side-effect-free. The other is that it causes cancer and organ failure. The pooled evidence supports neither.
Gallbladder disease is the serious risk with the clearest signal. It rose 26% across 99,599 GLP-1 patients and roughly 2.6-fold versus placebo in obesity trials.24 Rapid weight loss independently promotes gallstones, so the drug and the weight loss it causes are hard to separate — but the increase is not in doubt.
Pancreatitis sits in an honest grey zone. It is a labelled warning and shows up as a disproportionate real-world reporting signal,5 yet randomised-trial meta-analyses have not found a statistically significant increase.2 Reporting signals flag hypotheses; they cannot give you a rate or prove cause.
The thyroid warning is rodent data. The boxed warning exists because rodents given semaglutide developed thyroid C-cell tumours. The FDA itself states the human relevance is undetermined, and the large pooled analysis found no increase in new cancers.2 It is a genuine unknown, not a demonstrated human risk.
Delayed stomach emptying matters most before an operation. Because semaglutide slows gastric emptying, food can remain in the stomach longer than an anaesthetist would expect, raising aspiration risk during sedation.3 Anyone facing surgery needs to disclose GLP-1 use.
Who should not take it
The prescribing information lists semaglutide as contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a prior serious hypersensitivity reaction to it. It is not recommended in pregnancy.3
Documented caution applies to: previous pancreatitis or gallstone disease; existing diabetic retinopathy, especially alongside insulin; anyone on insulin or a sulfonylurea, because of added hypoglycaemia risk; severe pre-existing gastrointestinal disease or gastroparesis; people prone to dehydration; and anyone scheduled for surgery or sedation.3 This is a list of documented signals, not personalised guidance — only a clinician who knows the individual can weigh them.
What happens if you stop
Most of the gastrointestinal effects resolve when treatment stops, since they are driven by ongoing drug exposure. The weight does not stay off. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within a year of withdrawal, and the cardiometabolic improvements reverted with it.7 That is a durability finding rather than a side effect, but it belongs in any honest picture of what to expect.
What the evidence still cannot tell you
Unknown is not the same as safe. Three real gaps:
- Long-term safety beyond a few years. The longest large controlled trial, SELECT, followed participants for a mean of about 3.3 years.8 Nothing rigorous exists on a decade of continuous use, or on repeated stopping and restarting.
- Rare cancers cannot be ruled in or out. Pancreatic and thyroid cancers are rare enough that trials of this size are underpowered to confirm or exclude a small increase. Absence of a signal is reassuring, not conclusive.
- Individual risk is not predictable. Pharmacovigilance data describe populations. They cannot tell one person whether they will be in the 44% who feel nauseated or the 4.3% who stop.
Why research-grade semaglutide is a separate question
Every number on this page was generated with pharmaceutical-grade semaglutide, manufactured to regulatory standards, dosed on a defined schedule, under medical supervision. None of that describes material sold as a research chemical. Identity, purity, sterility and actual peptide content are unverified, which adds risks nothing in the literature has measured — on top of the drug’s own profile. The correct conclusion is not “the same risk” but “an unquantified risk in addition to a known one”.
For reconstitution arithmetic and concentration recordkeeping in a laboratory context, see our semaglutide dosage reference, the semaglutide vial protocol, the general peptide dosage calculator and the peptide reconstitution guide. These document measurements accurately; they are not human-use instructions and they do not reduce any risk described above. For the dual-agonist comparison, see tirzepatide side effects and AOD-9604 versus semaglutide.
Frequently Asked Questions
How long do semaglutide side effects last?
In pooled STEP trial data, the median episode of nausea lasted 8 days, diarrhoea 3 days and vomiting 2 days. Constipation was the outlier at a median of 47 days, with its prevalence levelling off around week 10. Episodes recur around each dose increase rather than running continuously.
When do semaglutide side effects start?
Gastrointestinal events occur most frequently during or shortly after each dose escalation, and the approved schedule steps the dose up every four weeks from 0.25 mg to 2.4 mg. So the first symptoms typically follow the first injections, and new waves tend to follow each step up.
Do the side effects mean it is working?
No. Weight loss was similar in trial participants with and without gastrointestinal events (11.4–17.7% versus 9.6–17.1%), and a mediation analysis attributed under one percentage point of the extra weight loss to those events. Feeling sick is not the mechanism and not a sign of a better result.
Are semaglutide side effects dangerous?
Overwhelmingly not: 99.5% of gastrointestinal events in the pooled trials were non-serious and 98.1% mild-to-moderate. Serious events do occur — gallbladder disease, pancreatitis, bowel obstruction, kidney injury from dehydration. Severe or persistent abdominal pain, ongoing vomiting or signs of gallstones warrant prompt medical attention.
Does semaglutide cause thyroid cancer?
This has only been shown in rodents. The FDA boxed warning states that the human relevance is undetermined, and a pooled analysis of 99,599 GLP-1 patients found no increase in new cancers. It remains contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
How many people stop taking it because of side effects?
Across 68 weeks of pooled STEP data, 4.3% discontinued permanently because of gastrointestinal events; in STEP 1 the figure was 4.5% versus 0.8% on placebo. The large majority tolerated treatment well enough to continue to the end of the trial.
Is research-grade semaglutide as safe as the prescription drug?
The published safety data describe regulated pharmaceutical semaglutide only. Unregulated material has no human safety data and unverified identity, purity and dose, so its risks are at minimum the same and plausibly higher. Do not assume equivalence.
References
- Wharton S, Batterham RL, Bhatta M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105. PubMed
- Galli M, Benenati S, et al. Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients. J Am Coll Cardiol. 2025. PubMed
- US Food and Drug Administration. WEGOVY (semaglutide) injection — prescribing information. accessdata.fda.gov
- Safwan M, Bourgleh MS. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta-analysis. Ann Saudi Med. 2025;45(2). PubMed
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with GLP-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795–1797. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. PubMed
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. PubMed
Research use only. This page summarises published evidence and regulatory documents. It is not medical advice, diagnosis or treatment, and it is not human dosing guidance. Consult a qualified healthcare professional before making any medical decision.
